Skip to main content
. 2017 Jun 14;16(2):1826–1836. doi: 10.3892/mmr.2017.6773

Figure 3.

Figure 3.

Effects of HA on the migratory activity of EGF-activated ovarian cancer cells. (A) mRNA expression levels of HAS1, HAS2 and HAS3 in EGF-treated SK-OV-3 and Caov-3 cells were assessed using reverse transcription-polymerase chain reaction. (B and C) Migratory capabilities of EGF-stimulated ovarian cancer cells were calculated and plotted as percentage of migration following treatment with HA. Data are expressed as the mean ± standard error of the mean. *P<0.05, **P<0.01. C, control group; D, DMSO group; E, EGF-treated group; So, sorafenib-treated group; So + E, sorafenib- and EGF-treated group; HA, hyaluronan; EGF, epidermal growth factor; HAS, HA synthase.